Mamedica, a UK-basd provider of cannabinoid prescription medicines, today announced a £4.5 million (more than $6 million) funding round led by Casa Verde, the U.S.-based cannabis-focused venture capital firm founded by Snoop Dogg.
Casa Verde has backed cannabis companies including Dutchie, Metrc and Leaflink in the United States, and holds European positions in Cansativa and Sanity Group. The new capital will be used to scale Mamedica's operations by optimizing its in-house supply chain for efficiency and continuity of care, expanding access through a wider clinical network, advancing its proprietary digital healthcare platform with enhanced automation and compliance capabilities, and driving education around the integration of medical cannabis into mainstream healthcare.
Launched in 2022 by CEO and founder Jon Robson, Mamedica provides specialist treatment for chronic and neurological conditions including pain, anxiety, ADHD and depression. Its digital model enables remote consultations with specialist clinicians, with medication delivered nationwide by secure next-day courier. Since inception, Mamedica has treated more than 10,000 patients, with approximately 7,500 actively under care and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024 and expects to double patient numbers annually as the UK medical cannabis industry approaches £1 billion in annual sales by the end of 2028.
